ASCO GI 2024 | Implications of the post-hoc Q-TWiST analysis of fruquintinib in refractory mCRC

Sebastian Stintzing, MD, Charité – Universitätsmedizin Berlin, Berlin, Germany, discusses the implications of the post-hoc Q-TWiST analysis of the Phase II FRESCO-2 (NCT04322539) trial assessing the quality-adjusted survival benefit of fruquintinib (F) + best supportive care (BSC) versus placebo (P) + BSC in heavily pretreated patients with refractory metastatic colorectal cancer (mCRC). The overall quality-adjusted time with F + BSC (Q-TWiST) was 2.04 months longer, demonstrating a clinically meaningful benefit in quality-adjusted survival. He highlights two important implications. Firstly, there’s a positive impact on the quality of life for patients, demonstrating that the administration of fruquintinib in this specific treatment area can prolong it. Secondly, there are regulatory implications, as this prolongation not only adds quality-adjusted life years but also contributes to a period without toxicity, a crucial aspect in the management of patients at this stage of the disease. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.